The Medical Imaging and Health ICT industries are recognised as key innovative sectors in healthcare. Already the impact of new medical technologies is extending beyond the clinical sphere into process improvements and workflow efficiencies that can improve patient safety and deliver financial gains.
COCIR considers that there is an opportunity to have a common EU approach to Health Technology Assesment (HTA) that brings uniform, predictable and transparent methodology and criteria.
In this regard, COCIR issued a position paper in October 2010 providing an industry perspective on the role of HTA and setting out a list of expectations of future HTA processes. If used appropriately COCIR believes that HTAs, when transparently conducted, can be a useful evaluation tool for decision makers to better ensure the efficient use of, and access to, healthcare resources.
While COCIR continues to recognise the crucial role of HTA for assessing the added value of medical technologies, we want also to stress the need for an appropriate HTA methodology. Therefore COCIR issued a new position paper with a set of recommendations towards the HTA agencies in October 2014.
DG SANCO created this initiative in order to bring National Agencies on HTA together. In addition a Stakeholder forum was created in order to channel the voice of other key stakeholders, inlcuding industry. COCIR has been a full industry member of the EUnetHTA JA 1 Stakeholder Forum and since then, have been actively contributing in the work of the Forum. Experts were nominated in the Stakeholder Advisory Groups (SAG) of the WP4 on core HTA and the WP7 on new technologies.
COCIR continues to be active within EUnetHTA initiative, and is currently examining how best to contribute in JA3, which will be officially launched March 3, 2016.
The Task Force gathers company experts, and its primary mission is to keep abreast of developments regarding HTA of relevant medical devices at the European level, and influence policy as much as possible to ensure that HTA does not impair market access for relevant medical devices.